Marker Therapeutics (MRKR) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Marker Therapeutics (MRKR) over the last 8 years, with Q3 2025 value amounting to -$0.12.
- Marker Therapeutics' EPS (Weighted Average and Diluted) rose 5384.62% to -$0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.23, marking a year-over-year decrease of 1388.89%. This contributed to the annual value of -$1.2 for FY2024, which is 28122.02% down from last year.
- Latest data reveals that Marker Therapeutics reported EPS (Weighted Average and Diluted) of -$0.12 as of Q3 2025, which was up 5384.62% from -$0.29 recorded in Q2 2025.
- Marker Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at -$0.01 for Q4 2023, and its period low was -$1.19 during Q1 2022.
- Its 4-year average for EPS (Weighted Average and Diluted) is -$0.39, with a median of -$0.29 in 2025.
- As far as peak fluctuations go, Marker Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 9841.23% in 2023, and later tumbled by 580352.63% in 2024.
- Quarter analysis of 4 years shows Marker Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.45 in 2022, then skyrocketed by 98.41% to -$0.01 in 2023, then tumbled by 5803.53% to -$0.42 in 2024, then surged by 71.55% to -$0.12 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.12 for Q3 2025, versus -$0.29 for Q2 2025 and -$0.4 for Q1 2025.